Please use this identifier to cite or link to this item:
|Title:||Biodistribution, dosimetry and imaging of 225Ac-DOTA-anti-PD-L1-BC in a murine immunocompetent transgenic breast cancer model|
|Authors:||JOSEFSSON ANDERS; NEDROW JESSIE; PARK SUNJU; BAECK TOM; HOBBS ROBERT F.; BRAYTON CORY; BRUCHERTSEIFER FRANK; MORGENSTERN ALFRED; SGOUROS G.|
|Publisher:||European Commission - Joint Research Centre|
|Type:||Articles in periodicals and books|
|Abstract:||The recent development of immunomodulatory agents have brought immunotherapy up as a possible treatment against various types of cancers. This treatment approach is based on tumors avoiding immune system recognition by co-opting immune checkpoints intended to prevent autoimmunity. One of the immune checkpoint mediators is the Programmed Cell Death protein 1 (PD-1) receptor. PD-1 interacts with Programmed cell Death Ligand 1 (PD-L1). PD-L1 is expressed on a variety of tumor cells, tumor associated macrophages and other cells in the tumor microenvironment. Clinical trials of anti-PD-L1 antibodies have yielded promising results in patient populations, which have exhausted all other conventional therapeutic options. In addition a number of studies have shown the potential of combined immune checkpoint inhibition therapy and external beam radiotherapy. In this study we examine the feasibility of a 225Ac-labeled anti-PD-L1 antibody to deliver an alpha-particle emitting radionuclide in a murine immunocompetent transgenic breast cancer model.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.